Fierce Pharma17h
As FDA's Peter Marks resigns, industry watchers size up vaccine, cell and gene therapy hits
As the FDA wavers from cuts, changes and departures under the second Trump administration, another vital figure of the agency ...
Fierce Pharma16h
FDA reviews Novo Nordisk's bid to expand Rybelsus as oral GLP-1 cuts heart disease risks
Novo Nordisk already has broad FDA approvals in hand for its injected semaglutide products Ozempic and Wegovy to reduce the ...
Fierce Pharma15h
AstraZeneca bulks up Imfinzi's prowess with FDA nod in bladder cancer around surgery
AstraZeneca has secured another expansion of its Imfinzi for use in cancer patients before and after surgery. | Imfinzi is ...
Fierce Pharma18h
Merck's Winrevair slashes mortality-morbidity risk by 76%
The interim results of a phase 3 trial of Merck’s pulmonary arterial hypertension (PAH) treatment Winrevair were so ...
Fierce Pharma17h
Judge levies $1.64B penalty on Johnson & Johnson in HIV drug marketing case
Nearly a year after a jury decided that Johnson & Johnson should be fined just over $150 million in a lawsuit alleging that ...
Fierce Pharma20h
"Drug loss" opens the door even further for the Japanese market entry
A growing concern in Japan, but there is something new on the horizon. | Japan faces a growing "Drug Loss" issue, but ...